NP_006209.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
NCBI Official Synonym Full Names
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
NCBI Official Synonym Symbols
MCM; CWS5; MCAP; PI3K; CLOVE; MCMTC; PI3K-alpha; p110-alpha [Similar Products]
NCBI Protein Information
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
UniProt Protein Name
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
UniProt Synonym Protein Names
Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; PtdIns-3-kinase subunit p110-alpha; p110alpha; Phosphoinositide-3-kinase catalytic alpha polypeptide; Serine/threonine protein kinase PIK3CA (EC:2.7.11.1
UniProt Synonym Gene Names
PI3-kinase subunit alpha; PI3K-alpha; PI3Kalpha; PtdIns-3-kinase subunit alpha; PtdIns-3-kinase subunit p110-alpha; p110alpha [Similar Products]
UniProt Entry Name
PK3CA_HUMAN
NCBI Summary for PIK3CA
Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq, Apr 2016]
UniProt Comments for PIK3CA
PIK3CA: Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4- phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5- bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation in breast cancer cells through the PDPK1- AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. Has also serine-protein kinase activity: phosphorylates PIK3R1 (p85alpha regulatory subunit), EIF4EBP1 and HRAS. Heterodimer of a catalytic subunit PIK3CA and a p85 regulatory subunit (PIK3R1, PIK3R2 or PIK3R3). Interacts with IRS1 in nuclear extracts. Interacts with RUFY3. Interacts with RASD2. Interacts with APPL1. Interacts with HRAS1 and KRAS. Interaction with HRAS1/KRAS is required for PI3K pathway signaling and cell proliferation stimulated by EGF and FGF2. Belongs to the PI3/PI4-kinase family.
Protein type: Motility/polarity/chemotaxis; EC 2.7.11.1; EC 2.7.1.153; Oncoprotein; Kinase, lipid; Carbohydrate Metabolism - inositol phosphate
Chromosomal Location of Human Ortholog: 3q26.3
Cellular Component: cytosol; lamellipodium; phosphoinositide 3-kinase complex; plasma membrane
Molecular Function: 1-phosphatidylinositol-3-kinase activity; ATP binding; insulin receptor substrate binding; kinase activity; phosphatidylinositol-4,5-bisphosphate 3-kinase activity; phosphatidylinositol-4-phosphate 3-kinase activity; phosphoinositide 3-kinase activity; protein binding; protein kinase activator activity; protein serine/threonine kinase activity
Biological Process: activation of protein kinase activity; angiogenesis; cardiac muscle contraction; endothelial cell migration; epidermal growth factor receptor signaling pathway; glucose metabolic process; leukocyte migration; liver development; negative regulation of neuron apoptosis; phosphatidylinositol biosynthetic process; phosphoinositide phosphorylation; phosphoinositide-mediated signaling; platelet activation; positive regulation of peptidyl-serine phosphorylation; protein amino acid phosphorylation; protein kinase B signaling cascade; regulation of cellular respiration; regulation of gene expression; regulation of multicellular organism growth; regulation of phosphoinositide 3-kinase cascade; T cell costimulation; T cell receptor signaling pathway; vascular endothelial growth factor receptor signaling pathway; vasculature development
Disease: Breast Cancer; Colorectal Cancer; Congenital Lipomatous Overgrowth, Vascular Malformations, And Epidermal Nevi; Cowden Syndrome 5; Gastric Cancer; Hepatocellular Carcinoma; Keratosis, Seborrheic; Lung Cancer; Megalencephaly-capillary Malformation-polymicrogyria Syndrome; Nevus, Epidermal; Ovarian Cancer
Research Articles on PIK3CA
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-PIK3CA antibody
Pathways associated with anti-PIK3CA antibody
Diseases associated with anti-PIK3CA antibody
Organs/Tissues associated with anti-PIK3CA antibody
|